AZ-AXWAY
8.9.2020 20:35:08 CEST | Business Wire | Press release
Axway (Euronext: AXW.PA), a leading provider of API Management and integration software, has been awarded the 2020 API Award for Best in Microservices Infrastructure. The award celebrates technical innovation, adoption and reception in the API & Microservices industries and use by a global developer community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005921/en/
“We are delighted to win Best in Microservices Infrastructure from API World,” said Vince Padua, Axway Chief Technology and Innovation Officer. “This award builds on the recognition we’ve received from other industry analysts such as Forrester Research, Inc. where we scored 5 out of 5 in the microservices support and integration criterion in The Forrester Wave™: API Management Solutions, Q3 2020 .¹ Microservices and APIs power innovation and are a critical component to enterprise solutions that impact the bottom line, growth, innovation and collaboration.”
Across the globe, thousands of companies count on Axway’s API solutions, including AVEM, the leader in France for cashless card services for banks and large retailers. AVEM uses AMPLIFY API Management to expose 80 microservices via its central API catalog. These new services have the potential to digitize and automate many common customer journeys, such as requesting changes to a contract, ordering consumables and requesting payment terminal repairs.
“We were faced with an important choice: either develop a one-off solution for each client, or seize the opportunity to transform our business with an API-enabled architecture,” said Farid Latti, Manager, Architecture and Security, AVEM. “We were confident that building a reusable solution would enable us to cut onboarding times for new banking clients dramatically, and we looked for an expert partner to help us. Our work with Axway is making it easier than ever for our clients to consume our payments processing services.”
“Axway is helping empower developers and engineers to build upon the backbone of the multi-trillion-dollar market for API-driven products and services,” said Jonathan Pasky, Executive Producer & Co-Founder of DevNetwork, producer of API World and the 2020 API Awards. “Today’s cloud-based SaaS software and hardware increasingly is powered by an open ecosystem of API-centric architecture. Axway’s win is evidence of their leading role in the growth of the API Economy.”
The award will be formally presented during API World 2020 Virtual , October 27-29, 2020.
¹The Forrester Wave™: API Management Solutions, Q3 2020, Forrester Research, Inc., August 4, 2020
About Axway
Axway revitalizes heritage IT infrastructures, helping more than 11,000 customers accelerate their digital journeys, add new business capabilities, and drive growth. With the AMPLIFY™ platform which combines APIs, MFT, B2B integration, and content services – we guide innovation and enhance the customer experience faster and more securely than ever. axway.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005921/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom